Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia

Leukemia. 2004 Jan;18(1):182. doi: 10.1038/sj.leu.2403115.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Dose-Response Relationship, Drug
  • Female
  • Fusion Proteins, bcr-abl / antagonists & inhibitors
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Piperazines / adverse effects*
  • Piperazines / therapeutic use
  • Porphyria Cutanea Tarda / chemically induced*
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl